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Abstract
Purpose
To compare the concordance in risk classification between the EndoPredict and the Mam-
maPrint scores obtained for the same cancer samples on 40 estrogen-receptor positive/
HER2-negative breast carcinomas.
Methods
Formalin-fixed, paraffin-embedded invasive breast carcinoma tissues that were previously
analyzed with MammaPrint as part of routine care of the patients, and were classified as
high-risk (20 patients) and low-risk (20 patients), were selected to be analyzed by the Endo-
Predict assay, a second generation gene expression test that combines expression of 8
genes (EP score) with two clinicopathological variables (tumor size and nodal status, EPclin
score).
Results
The EP score classified 15 patients as low-risk and 25 patients as high-risk. EPclin re-classi-
fied 5 of the 25 EP high-risk patients into low-risk, resulting in a total of 20 high-risk and 20
low-risk tumors. EP score and MammaPrint score were significantly correlated (p = 0.008).
Twelve of 20 samples classified as low-risk by MammaPrint were also low-risk by EP score
(60%). 17 of 20 MammaPrint high-risk tumors were also high-risk by EP score. The overall
concordance between EP score and MammaPrint was 72.5% (κ = 0.45, (95% CI, 0.182 to
0.718)). EPclin score also correlated with MammaPrint results (p = 0.004). Discrepancies
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between both tests occurred in 10 cases: 5 MammaPrint low-risk patients were classified as
EPclin high-risk and 5 high-risk MammaPrint were classified as low-risk by EPclin and over-
all concordance of 75% (κ = 0.5, (95% CI, 0.232 to 0.768)).
Conclusions
This pilot study demonstrates a limited concordance between MammaPrint and EndoPre-
dict. Differences in results could be explained by the inclusion of different gene sets in each
platform, the use of different methodology, and the inclusion of clinicopathological parame-
ters, such as tumor size and nodal status, in the EndoPredict test.
Introduction
The decision on adjuvant treatment for breast cancer patients is based on risk assessment
using clinicopathological criteria, such as patient age, menopausal status, axillary lymph node
status, tumor size, tumor grade, estrogen receptor (ER)/progesterone receptor (PgR) expres-
sion, HER2 status, and Ki67 score. However, adjuvant treatment decision making in women
with ER+/HER2- early breast cancer remains as a difficult task. Routinely, all these patients
will receive adjuvant hormonal treatment. A substantial proportion of these patients are also
treated with adjuvant chemotherapy, although a significant part of these will not benefit from
this treatment [1]. Thus, a major challenge for clinical oncologists is to identify those patients
who will not benefit for adjuvant chemotherapy, and those who are more likely to develop
recurrence, so that the most appropriate therapeutic regime can be administered in each case
[1,2].
In recent years, molecular characterization of breast cancer has contributed to improving
our understanding of breast cancer as a complex disease, and led to the development of a vari-
ety of prognostic and predictive gene signatures that may also be useful in recurrence predic-
tion and treatment decision making [3]. These molecular tests provide useful prognostic and
predictive information that is independent of standard clinicopathological information, and
may be particularly helpful in cases for which measures of clinical risk are equivocal (i.e.,
small, node-negative, intermediate grade tumors) [4]. However, these genomic tests are based
in different methodology and measure different genes. Moreover, they have been validated
clinically in different cohorts from randomized clinical trials with long-term clinical outcomes.
Recent studies highlight the functional and clinically relevant impact of these multigene prog-
nostic assays upon the adjuvant chemotherapy in ER+ early-stage breast carcinoma, indicating
chemotherapy changes in approximately 25–30% of patients, with more changes against than
for adjuvant chemotherapy [5].
One of the most widely used test is the MammaPrint (MP) assay (Agendia Laboratories,
Amsterdam, The Netherlands), which is a prognostic score performed by a central laboratory
that was cleared by the FDA in 2007. MP was initially limited by its requirement for fresh
tissue, but it is now validated for formalin-fixed, paraffin-embedded (FFPE) tissue [6]. MP
measures the expression of 70 genes using a microarray platform, and reports a binary risk
classification (low-risk or high-risk) for recurrence without adjuvant chemotherapy. This
information is intended to spare patients at low-risk of recurrence from receiving adjuvant
chemotherapy, with its attendant morbidity [7]. More recently developed, the EndoPredict
assay (EP) (Sividon Diagnostics GmbH, Cologne, Germany), is a test based on gene expression
data in combination with two clinicopathological risk parameters (tumor and nodal status) to
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assess the risk of distant metastasis in patients with ER+/HER2- primary breast cancer if
treated with adjuvant endocrine therapy alone [8]. This test measures the expression of eight
cancer-related genes of interest (BIRC5, UBE2C,DHCR7, RBBP8, IL6ST, AZGP1, MGP and
STC2) and three reference genes (CALM2, OAZ1 and RPL37A) to calculate a molecular risk
score (EP score). The molecular risk score is then combined with the nodal status and tumor
size resulting in a molecular-clinicopathological hybrid score (EPclin score) with improved
prognostic power. Using a predefined cutoff value, patients are stratified into low- or high-risk
of distant recurrence. The test can be carried out on routinely processed and archived FFPE
tissue, and is designed to be performed decentrally [9,10]. EP was validated in three random-
ized phase III trials with patients with ER+/HER2-, node-negative and node-positive breast
carcinomas [8,11]. The EP provided additional prognostic information to conventional risk
factors such as grading, quantitative ER, or Ki67 and outperformed risk classification by clini-
cal guidelines. Moreover, it could be demonstrated that EP is prognostic for early and late
metastasis [11,12]. The EPclin score was also directly compared to purely clinical risk classifi-
cations (like St. Gallen, German S3, and NCCN) and found to be superior to these classifiers
[12].
The main objective of this study was to compare retrospectively the concordance in risk
classification between the EndoPredict and the MammaPrint tests in 40 ER+/HER2- breast
carcinomas. We further compared TargetPrint (Agendia Laboratories), a commercially avail-
able mRNA-based gene expression test that quantitatively determines gene expression levels of
ER, PgR, and HER2 with conventional immunohistochemistry/FISH analysis of ER, PgR, and
HER2.
Materials and methods
Ethical standards
The study was approved by the Ethics Committee of the University Hospital La Paz, Madrid,
Spain (code HULP: PI-2146). Patients provided written consent for their samples to be used in
this study.
Patients and tumor samples
This study involved 40 patients with ER+/HER2- breast carcinomas tests which were previ-
ously categorized as low-risk (20 patients) or high-risk (20 patients) with MammaPrint as part
of routine care of the patients. The main criterion for the selection of the patients was the result
of the MammaPrint test (low-risk versus high-risk). All patients underwent surgery between
March 2012 and December 2015 at the University Hospital La Paz, Madrid, Spain. Data on age
and tumor characteristics were collected for all patients. The surgical specimens were fixed in
10% buffered formalin and embedded in paraffin. Four-μm thick sections were stained with
hematoxylin-eosin for histological diagnosis. Sections (10μm) with at least 40% of tumor cellu-
larity were selected for the study.
Immunohistochemistry for ER/PgR/HER2 and Ki67 and fluorescence in
situ hybridization (FISH) for HER2
All cases were reviewed by two breast pathologists (DH and LY) to assess tumor grade (using
the Nottingham histological three-tier grading system), tumor size, nodal status, ER, PgR,
HER2, and Ki67 expression. The expression of ERα (clone EP1; Dako, Glostrup, Denmark,
prediluted), PgR (clone PgR1294; Dako, prediluted), and Ki67 (clone MIB1; Dako, prediluted)
were determined by immunohistochemistry (IHC) during routine pathologic examination.
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ER and PgR status was determined based on the percentage of positive nuclei in the invasive
neoplastic compartment of the tissue. Tumors were classified as ER- or PgR-positive when
1% invasive tumor cells showed definite nuclear staining, regardless of staining intensity.
Ki67 was evaluated as the percentage of positively stained nuclear cancer cells (regardless of
staining intensity). HER2 expression was evaluated with the HercepTest kit (Dako) and scored
as 0, 1+, 2+, or 3+, according to the ASCO-CAP guidelines. Tumors scored as 2+ were re-
tested with FISH using the HER2 IQFISH PharmDx kit (Dako).
Mammaprint test
The MammaPrint test was performed on representative paraffin blocks of the breast carcino-
mas at the centralized Agendia Laboratories (Amsterdam, The Netherlands) blinded for
clinical and histological data as part of routine care of the patients included in this study. Tar-
getPrint assay was also performed in these cases.
EndoPredict test
The same tumor tissue block used for MammaPrint testing in each patient was used for EP
test. RNA extraction was performed as previously described [9]. Total RNA was extracted
from one 10-μm whole FFPE tissue section using a silica-coated magnetic bead-based method
with Tissue Preparation Reagents (Sividon Diagnostics). Expression of eight genes of interest
(AZGP1, BIRC5, DHCR7, IL6ST, MGP, RBBP8, STC2, UBE2C), three normalization genes
(CALM2, OAZ1, RPL37A) as well as the amount of residual genomic DNA (HBB) were
assessed by the EP assay (Sividon Diagnostics). Gene expression was analyzed by one-step RT-
qPCR using the SuperScript III PLATINUM One-Step Quantitative RT-PCR System with
ROX (Invitrogen, Karlsruhe, Germany) according to manufacturer’s instructions in a VER-
SANT1 kPCR Molecular System (Siemens Healthcare Diagnostics, Erlangen, Germany). EP
and EPclin scores were determined as published earlier [8,9] using the EndoPredict Report
Generator software which is available online (www1.endopredict.com). The predefined cutoffs
for diagnostic decisions were applied to stratify patients into low- or high-risk groups: EP low-
risk (<5), EP high-risk (5); EPclin low-risk (<3.3), EPclin high-risk (3.3). The EPclin cut
off value corresponds to a 10% distant recurrence rate at 10 years.
Statistical analyses
The concordance between EP and MP was analyzed using Cohen’s kappa and Fisher’s exact
test. The association between the clinicopathological features and EP and EPclin scores was
analyzed using the Pearson correlation or Fisher’s exact test, as appropriate. The correlation
between the Ki67 and EP and EPclin scores was examined using the Pearson correlation coeffi-
cient. Agreement measurements between binary (positive versus negative) TargetPrint mRNA
and IHC classifications were based on two-way contingency table analysis and included overall
correlation and positive agreement (defined as the number of samples classified positive by
both IHC and mRNA divided by the number of positive samples using IHC) [13]. Statistical
analysis was performed with the SPSS statistics 19 software (IBM, Armonk, NY, USA).
Results
Patient characteristics
The characteristics of the 40 patients included in this study are summarized in Table 1. The
detailed clinical, pathological, immunohistochemical and molecular data of the patients are
shown in S1 Table.
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MammaPrint test
MammaPrint test classified the breast carcinomas as low-risk in 20 patients and high-risk in
20 patients.
EndoPredict test
According to the molecular EP score 15 patients were classified as low-risk and 25 patients as
high-risk. The EPclin score (combining EP score with tumor size and nodal status) re-classi-
fied 5 of the 25 EP high-risk patients into the low-risk group resulting in 20 patients with low-
and 20 patients with high-risk of distant recurrence. The clinicopathological characteristics of
the patients according to EPclin score are summarized in Table 2.
Correlation and concordance between EP scores (EP molecular score
and EPclin score) and MammaPrint test results
EP molecular scores and MP scores were significantly correlated (p = 0.008). Twelve of 20
samples classified as low-risk by MP were also low-risk by EP score (60%). Seventeen of 20 MP
high-risk samples were also EP high-risk (85%). The overall concordance between both risk
Table 1. Characteristics of the 40 patients included in the study.
Characteristics Patients N = 40 (%)
Age at diagnosis (years)
55 17 (42.5)
>55 23 (57.5)
Histology
Ductal 34 (85)
Lobular 6 (15)
Tumor grade
1 8 (20)
2 22 (55)
3 10 (25)
Tumor size
pT1b (0.5 to 1 cm) 9 (22.5)
pT1c (>1 to 2 cm) 22 (55)
pT2 (>2 to 5 cm) 9 (22.5)
Nodal status
Negative 32 (80)
Positive* 8 (20)
ER status
Positive 40 (100)
Negative 0 (0)
PgR status
Positive 38 (95)
Negative 2 (5)
HER2 status
Positive 0 (0)
Negative 40 (100)
ER, estrogen receptor; PgR, progesterone receptor;
*All micrometastases (pN1mi)
https://doi.org/10.1371/journal.pone.0183452.t001
Comparison of risk classification between EndoPredict and MamaPrint in breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0183452 September 8, 2017 5 / 12
classifications was 72.5% (Table 3). Cohen’s κ was calculated to determine the agreement
between EP and MP in risk stratification. There was a moderate agreement between the two-
molecular test, κ = 0.45 (95% CI, 0.182 to 0.718), p< .0005.
The EPclin score also correlated with the MP results (p = 0.004). Fifteen of 20 samples clas-
sified as low-risk by MP were also low-risk by EPclin score (75%). Similarly, 15 of 20 MP high-
risk patients were EPclin high-risk (75%). Overall concordance was 75% (Table 4). Cohen’s κ
between EPclin and MP was κ = 0.5 (95% CI, 0.232 to 0.768), p< .0005.
Correlation of proliferation index Ki67 to EP molecular and EPclin scores
There was a statistically significant but moderate correlation between the EP score and Ki67
(Pearson coefficient = 0.535, p = 0.01) (Fig 1A). No significant correlation was found between
EPclin score and Ki67 proliferation index (Pearson coefficient = 0.37, p = 0.05) (Fig 1B).
Table 2. Clinical characteristics of the patients classified as high- or low-risk for distant metastasis by EPclin score.
EndoPredict EPclin Low-risk n = 20 EndoPredict EPclin High-risk n = 20 P-value
Age (years)
55 8 9 0.784
>55 12 11
Histology
Ductal 16 18 0.652
Lobular 4 2 0.292
Tumor grade
1 5 3 0.429
2 13 9 0.204
3 2 8 0.028
Tumor size
pT1b 5 4 0.705
pT1c 13 9 0.204
pT2 2 7 0.050
Nodal status
Positive* 3 5 0.625
Negative 17 15
*All micrometastases (pN1mi)
https://doi.org/10.1371/journal.pone.0183452.t002
Table 3. Comparison of EPscore and MammaPrint based risk classification.
EP score
n = 40 Low-risk High-risk
Mammaprint Low-risk 12 (60%) 8 (40%)
High-risk 3 (15%) 17 (85%)
https://doi.org/10.1371/journal.pone.0183452.t003
Table 4. Comparison of EPclin score and MammaPrint based risk classification.
EPclin score
n = 40 Low-risk High-risk
Mammaprint LowRisk 15 (75%) 5 (25%)
High Risk 5 (255%) 15 (75%)
https://doi.org/10.1371/journal.pone.0183452.t004
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Comparison of ER/PgR/HER2 status with conventional IHC/FISH and
TargetPrint
Qualitative IHC/FISH (positive versus negative) showed a high concordance with TargetPrint
readout (Table 5): of the 40 ER-positive cases by IHC, 39 (97.5%) were TargetPrint ER+. The
only discordant case showed ER positivity in approximately 85% of tumor nuclei on IHC but
was assessed as negative with TargetPrint. This case was PgR+/HER2- by IHC and Target-
Print with a proliferation index (Ki67) of 6%, and was classified as low-risk by both tests, MP
and EPclin. For PgR, the positive agreement was 81.6%. Thus, 31 PgR+ cases (77.5%) by IHC
were also PgR+ by TargetPrint. Of the 9 discordant cases, 7 tumors were PgR+ by IHC but
were classified as PgR- by TargetPrint whereas 2 cases were PgR- by IHC but PgR+ by Target-
Print. Of the 40 HER2- cases by IHC/FISH, 39 (97.5%) were TargetPrint HER2-. The only
discordant case was HER2- by both, IHC and FISH, and corresponded to an ER+/PgR+
tumor with a proliferation index (Ki67) of 20%, and was classified as high-risk by both tests,
MP and EP.
Fig 1. Comparison of proliferative index (Ki67) with EP score (A) and EPclin score (B). r = Pearson coefficient.
https://doi.org/10.1371/journal.pone.0183452.g001
Table 5. Comparison of ER/PgR/HER2 status by IHC/FISH and TargetPrint.
ER status IHC ER+ IHC ER-
TargetPrint ER+ 39 (97.5%) 0
TargetPrint ER- 1 (2.5%) 0
PgR status IHC PgR+ IHC PgR-
TargetPrint PgR+ 30 (75%) 2 (5%)
TargetPrint PgR- 8 (20%) 0
HER2 status 3+ 2+/FISH+ 2+/FISH - Negative 0/1+
TargetPrint HER2+ 0 0 0 1 (2.5%)
TargetPrint HER2- 0 0 2 (5%) 37 (92.5%)
ER, estrogen receptor; PgR, progesterone receptor
https://doi.org/10.1371/journal.pone.0183452.t005
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Discussion
We compared retrospectively the concordance between EP scores (EP molecular score and
EPclin score) and MP scores in 40 ER+/HER2- breast carcinomas. We found a moderate con-
cordance between EP, EPclin and MP-based risk classifications with an overall concordance of
72.5% and 75% between EP molecular score and MP, and EPclin score and MP, respectively.
To the best of our knowledge, this is the first study comparing the concordance in risk
classification between the EndoPredict (EP/EPclin) and the MammaPrint tests in a series of
ER+/HER2- breast carcinomas. Interestingly, our study shows that despite the discrepancies
observed between EP and MP, both tests categorized the patients in the same proportion of
cases of high- and low-risk categories (50% each group). These results are similar to those
reported in previous studies comparing different gene expression signatures in breast cancer.
Comparison of the poor prognosis group of the MP and the intermediate- and high-risk
groups from the Oncotype DX recurrence-score (RS) models showed that their sample predic-
tions agreed in 77% of patients with ER+ early-stage breast carcinomas. These analyses suggest
that despite very little gene overlap and different algorithms used, the outcome predictions for
the majority of these patients would be similar [14]. The Optimal Personalised Treatment of
early breast cancer using Multiparameter Analysis preliminary study (OPTIMA prelim) com-
pared risk stratification and subtype classification of five multigene predictor tests (Oncotype
DX, Prosigna [PAM50], MammaPrint, MammaTyper, and NexCourse Breast [IHC4-AQUA])
performed in a series of 313 women with ER+/HER- early breast cancer that were randomized
to chemotherapy and endocrine therapy or test-directed (chemotherapy if Oncotype DX RS
>25) treatment [15]. Strikingly, although the five tests categorized similar numbers of tumors
as low- or high-risk categories there was only moderate agreement between tests at the individ-
ual patient level. Thus, 60.6% of tumors were assigned to different risk categories by different
tests (kappa ranges 0.33–0.60), although 94 (31.1%) showed agreement between four of five
tests [15]. Therefore, current multi-parameter tests seem to provide broadly equivalent risk
information in ER+/HER2- breast cancers at the population level; however, these tests may
provide different risk categorization for the individual patient [15]. Similar findings have been
described in a study comparing PAM50 and Oncotype DX [16]. In another study, Varga et al
reported that the concordance of classification in low- or high-risk between Oncotype DX
(combining the intermediate-risk and high-risk groups to one high-risk group) and EP risk
score and EPclin score was 76% and 65%, respectively [17].
Although most of the gene signatures currently available provide similar outcome predic-
tions in node-negative patients, significant differences across predictors are present in node-
positive disease, and for prediction of late metastasis with improved prognostic power of sec-
ond generation gene expression tests, such as EP. In this sense, TransATAC, the translational
study of the Arimidex, Tamoxifen, Alone or in Combination trial (ATAC), has recently
addressed the prognostic value of EP and EPclin for 10-year distant recurrence risk in post-
menopausal women with ER+/HER2- breast carcinomas, and compared their prognostic abil-
ity with that of the Oncotype DX RS [11]. This study confirmed the independent prognostic
ability of EP and EPclin in this cohort of patients. Moreover, EPclin demonstrated a better
prognostic ability than RS mainly because of its integration with clinicopathological factors
(nodal status and tumor size) but also because of a superior molecular algorithm able to pre-
dict late events better than RS, especially in node-positive patients [11]. This led Genomic
Health to develop an online Recurrence Score Pathology-Clinical (RSPC) calculator to use in
ER+/HER2-/node-negative breast cancer patients; RSPC combines RS with clinicopathological
variables, including patient age, tumor size, tumor grade, and planned adjuvant hormonal
therapy (tamoxifen or aromatase inhibitor) [18]. RSPC has demonstrated a significantly more
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prognostic value for distant recurrence compared with RS alone; additionally, it showed better
stratification of risk categories in the study population [19].
Multiple factors may contribute to the discrepancies between EP and MP scores. These dif-
ferences could be partly due to the different main biological motives covered by the genes
included in the test algorithms, such as proliferation or ER signaling. Some differences could
be explained by the coverage of other motives such as cell adhesion, invasion, or DNA repair,
as it has been demonstrated in previous studies comparing EP and Oncotype DX [17]. This
heterogeneity may also be attributed partially to the different methodologies that were used to
build both classifiers (cDNA microarray and qRT-PCR for MP and EP, respectively), and the
heterogeneity in the sample population used to develop the tests. Moreover, each technology
has unique normalization methods.
We observed a moderate statistically significant correlation between Ki67 and the EP score,
but no correlation between Ki67 and the EPclin score. Similar results have been reported by
Varga et al who performed a direct comparison of the concordance between Ki67 as a continu-
ous variable and the EP and EPclin scores in a series of 34 ER+ /HER2- breast carcinomas,
finding a moderate statistically significant correlation between Ki67 and the EP score (Pearson
coefficient 0.55, p<0.0001); no significant correlation was observed between the EPclin score
and Ki67 (Pearson coefficient 0.24, p = 0.16) [17]. Using the Ki67 cutoff of 14% Dubsky et al
divided over 1,000 patients into luminal A and B subtypes and found that the EPclin score can
subdivide these patients into two additional groups related to prognosis [12]. Similarly, Filipits
et al demonstrated that the EP score provided independent prognostic information in a multi-
variate analysis with conventional clinicopathological factors, including Ki67 (cutoff 11%) [8].
These data suggest that the EP molecular score will likely perform better than Ki67 alone for
the prognosis of breast cancer patients, but the performance of the EPclin score versus Ki67 is
less clear.
TargetPrint, a diagnostic test for the precise molecular readout of ER, PgR, and HER2
mRNA gene expression levels, was additionally analyzed in our series of patients. Our results
showed a high concordance between TargetPrint and IHC/FISH for ER (97.5%) and HER2
(97.5%), and moderate concordance for PgR (77.5%). These results are similar to those
reported previously, with concordances of approximately 96% for ER and 95% for HER2
[13,20]. Regarding PgR, the concordance for mRNA and IHC analysis has been shown to be
approximately 80% in previous studies [21,22]. However, mRNA-derived PgR status is more
strongly associated with clinical outcome and, therefore, mRNA could be more reliable for
assessing PgR receptor status [23]. The reasons for the discordant results between mRNA read-
out and IHC assessment of ER, PgR, and HER2 have not been elucidated so far. Suggested pos-
sible causes such as intratumoral heterogeneity, have still not been analyzed in a randomized
study [20].
The main limitations of this study are related to the moderate sample size which may have
limited the conclusions reached in the study. Thus, a further large-scale study including fol-
low-up data is necessary to validate our results.
In conclusion, this study is the first direct comparison of risk stratification between
EP/EPclin with MP. Our pilot study shows a limited concordance between EndoPredict and
MammaPrint results on individual patients although both tests classified the same proportion
of cases into high- and low-risk categories. Recent studies suggest that the addition of clinico-
pathological variables into these multigene predictor tests, such as EPclin, seems to improve
their prognostic ability [24,25]. Discrepant results between tests reflect the fact that the assays
are measuring different genes, using different methodology, and highlight the problems of pre-
dicting recurrence risk in ER+/HER2- breast cancer patients [26]. Further clinical studies eval-
uating large patient cohorts including follow-up data are needed to compare both tests.
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Supporting information
S1 Table. Detailed description of clinical, pathological, immunohistochemical, and molec-
ular data of the patients included in the study.
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